Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride.

Who Took Part

Patients (n = 233) from the CANDLE trial were randomly assigned to either the add-on canagliflozin (n = 113) or glimepiride treatment groups (n = 120).

The patients were followed-up for 24 weeks.

How the Study Was Run

The design is described as randomized.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 24 weeks.

The NT-proBNP levels were measured at baseline and after 24 weeks.

The LVEF was determined at baseline.

What Was Measured

The subject headings attached to it are Ventricular Function, Left, Stroke Volume, Canagliflozin, Diabetes Mellitus, Type 2, Heart Failure, Natriuretic Peptide, Brain and Peptide Fragments.

The authors tagged it with the keywords Left ventricular ejection fraction and N-terminal pro-brain natriuretic peptide.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) over 24 weeks.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Journal of cardiology), a journal based in Netherlands.

More context: the BNP (Nesiritide) compound page, all human trials.